Drug glucuronidation assays on human liver microsomes immobilized on microfluidic flow-through reactors

被引:9
作者
Kiiski, Iiro [1 ]
Ollikainen, Elisa [1 ]
Artes, Sanna [1 ]
Jarvinen, Paivi [1 ]
Jokinen, Ville [2 ]
Sikanen, Tiina [1 ]
机构
[1] Univ Helsinki, Fac Pharm, Div Pharmaceut Chem & Technol, Drug Res Program, POB 56,Viikinkaari 5E, FI-00014 Helsinki, Finland
[2] Aalto Univ, Sch Chem Engn, Dept Mat Sci & Engn, FI-02150 Espoo, Finland
基金
芬兰科学院;
关键词
Drug metabolism; Glucuronidation; Microreactors; Enzyme immobilization; Microfluidics; Microfabrication; HUMAN UDP-GLUCURONOSYLTRANSFERASES; CYTOCHROME-P450; ENZYMES; FATTY-ACIDS; METABOLISM; ALBUMIN; PHOSPHOLIPIDS; EXPLANATION; FABRICATION; PREDICTION; KINETICS;
D O I
10.1016/j.ejps.2020.105677
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
UDP-glucuronosyltransferases (UGTs), located in the endoplasmic reticulum of liver cells, are an important family of enzymes, responsible for the biotransformation of several endogenous and exogenous chemicals, including therapeutic drugs. However, the phenomenon of 'latency', i.e., full UGT activity revealed by disruption of the microsomal membrane, poses substantial challenges for predicting drug clearance based on in vitro glucuronidation assays. This work introduces a microfluidic reactor design comprising immobilized human liver microsomes to facilitate the study of UGT-mediated drug clearance under flow-through conditions. The performance of the microreactor is characterized using glucuronidation of 8-hydroxyquinoline (via multiple UGTs) and zidovudine (via UGT2B7) as the model reactions. With the help of alamethicin and albumin effects, we show that conducting UGT metabolism assays under flow conditions facilitates in-depth mechanistic studies, which may also shed light on UGT latency.
引用
收藏
页数:9
相关论文
共 34 条
[1]   MICROSOMAL IMMOBILIZED-ENZYME-REACTOR FOR ONLINE PRODUCTION OF GLUCURONIDES IN A HPLC COLUMN [J].
ALEBICKOLBAH, T ;
WAINER, IW .
CHROMATOGRAPHIA, 1993, 37 (11-12) :608-612
[2]  
[Anonymous], 2020, is influenced by interaction of drug-transporter polymorphisms in Mexican
[3]   CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe [J].
Backman, Janne T. ;
Honkalammi, Johanna ;
Neuvonen, Mikko ;
Kurkinen, Kaisa J. ;
Tornio, Aleksi ;
Niemi, Mikko ;
Neuvonen, Pertti J. .
DRUG METABOLISM AND DISPOSITION, 2009, 37 (12) :2359-2366
[4]   In vitro-in vivo correlations for drugs eliminated by glucuronidation:: Investigations with the model substrate zidovudine [J].
Boase, S ;
Miners, JO .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (05) :493-503
[5]  
EMA, 2012 GUID INV DRUG I
[6]   Altered AZT (3′-azido-3′-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance:: Comparison to hepatocytes and effect of incubation environment [J].
Engtrakul, JJ ;
Foti, RS ;
Strelevitz, TJ ;
Fisher, MB .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (11) :1621-1627
[7]  
Fisher MB, 2000, DRUG METAB DISPOS, V28, P560
[8]  
HOCHMAN Y, 1981, J BIOL CHEM, V256, P4783
[9]   Pharmacokinetics of raloxifene and its clinical application [J].
Hochner-Celnikier, D .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1999, 85 (01) :23-29
[10]   Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools [J].
Issa, Naiem T. ;
Wathieu, Henri ;
Ojo, Abiola ;
Byers, Stephen W. ;
Dakshanamurthy, Sivanesan .
CURRENT DRUG METABOLISM, 2017, 18 (06) :556-565